Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/ AKT pathway and suppresses breast cancer growth

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 427-435

  Li, Jie ^a   Zhang, Chao ^a   Jiang, Hongchuan ^a   Cheng, Jiao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Andrographolide (Andro); Breast cancer; HIF 1 ; Hypoxia; Inhibit; PI3k AKT mTOR pathway

Indexed keywords

ANDROGRAPHOLIDE; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

EID: 84923067446     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S76116     Document Type: Article

References (29)

1. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur J Cancer. 2008;44:2766–2773.
2. Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013;9:1623–1636.
3. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000;14:1983–1991.
4. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol. 2005;242:157–213.
5. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29:297–307.
6. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123:3664–3671.
7. Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 2008;8:19–26.
8. Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.
9. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510–5514.
10. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35:71–103.
11. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res. 2006;4:601–605.
12. Zhao J, Yang G, Liu H, et al. Determination of andrographolide, deoxyandrographolide and neoandrographolide in the Chinese herb Andrographis paniculata by micellar electrokinetic capillary chromatography. Phytochem Anal. 2002;13:222–227.
13. Reddy VL, Reddy SM, Ravikanth V, et al. A new bis-andrographolide ether from Andrographis paniculata nees and evaluation of anti-HIV activity. Nat Prod Res. 2005;19:223–230.
14. Shen YC, Chen CF, Chiou WF. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol. 2002;135:399–406.
15. Zhou J, Zhang S, Ong CN, et al. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem Pharmacol. 2006;72:132–144.
16. Rajagopal S, Kumar RA, Deevi DS, et al. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol. 2003;3:147–158.
17. Lang L, Liu X, Li Y, et al. A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth. PLoS One. 2014;9:e99584.
18. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–4613.
19. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002;277:27975–27981.
20. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995–4004.
21. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009;13:2780–2786.
22. Satyanarayana C, Deevi DS, Rajagopalan R, et al. DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells. BMC Cancer. 2004;4:26.
23. Shi MD, Lin HH, Lee YC, et al. Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chem Biol Interact. 2008;174:201–210.
24. Cheung HY, Cheung SH, Li J, et al. Andrographolide isolated from Andrographis paniculata induces cell cycle arrest and mitochondrial-mediated apoptosis in human leukemic HL-60 cells. Planta Med. 2005;71:1106–1111.
25. Lee YC, Lin HH, Hsu CH, et al. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol. 2010;632:23–32.
26. Lin HH, Tsai CW, Chou FP, et al. Andrographolide down-regulates hypoxia-inducible factor-1alpha in human non-small cell lung cancer A549 cells. Toxicol Appl Pharmacol. 2011;250:336–345.
27. Aprelikova O, Chandramouli GV, Wood M, et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem. 2004;92:491–501.
28. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205–38211.
29. Patiar S, Harris AL. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer. 2006;13(Suppl 1):S61–S75.